Aligos Therapeutics, Inc.
ALGS evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for ALGS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ALGS
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for chronic hepatitis B (HBV) and other liver and viral diseases, with its lead candidate pevifoscorvir sodium in Phase 2 trials.
Key risk: Going concern uncertainty
BioSniper Score
Based on 5 of 6 signals
Market Cap
$43.1M
Cash Runway
4.8 moLead Asset
ALG-055009 (Phase 2)
Next Catalyst
Phase2_Topline · Dec 31, 2026Financial data as of Jun 30, 2026.
Tracking 3 pipeline candidates · 6 clinical trials · 3 catalysts for Aligos Therapeutics, Inc..
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for chronic hepatitis B (HBV) and other liver and viral diseases, with its lead candidate pevifoscorvir sodium in Phase 2 trials.
- Lead drug candidate pevifoscorvir sodium is in an ongoing Phase 2 clinical trial for chronic HBV infection [sec_mda · as of 2026-08-06].
- Cash and equivalents were $30.4M as of 2026-06-30 [sec].
- The company has no revenue and reported a net loss of $1.5M for the period ending 2026-06-30 [sec].
- Substantial doubt exists about the company's ability to continue as a going concern for at least 12 months from the issuance of its financial statements [sec_mda · as of 2026-08-06].
- The company also has research programs in MASH and coronavirus indications [sec_mda · as of 2026-03-05].
What works
- Pevifoscorvir sodium is in Phase 2 trials, indicating clinical progress toward a potential treatment for chronic HBV [sec_mda · as of 2026-08-06].
- The company has a diversified pipeline with additional programs in MASH and coronavirus, providing multiple shots on goal [sec_mda · as of 2026-03-05].
- Aligos has experience operating as a public company and has previously raised substantial capital (e.g., $122.9M as of 2025) [sec_mda · as of 2025-08-06].
What to weigh
- The company has no approved products or revenue, and its ability to continue as a going concern is in doubt [sec_mda · as of 2026-08-06].
- Cash runway is limited; existing resources are expected to fund operations only into the third quarter of 2026 [sec_mda · as of 2026-03-05].
- Clinical development is expensive and uncertain, and the company may need to significantly reduce operations if additional funding is not secured [sec_mda · as of 2026-05-07].
- The company faces competition from other therapies for hepatological indications and viral diseases [sec_mda · as of 2026-03-05].
From the filings
Quoted directly from source documents.
Lead candidate pevifoscorvir sodium is in Phase 2 for chronic HBV.
“chronic HBV infection drug candidate pevifoscorvir sodium, for which we have an ongoing Phase 2 trial”
SEC MD&A · August 6, 2026
Substantial doubt about going concern.
“Our current operating plan and projected cash outflows for the upcoming periods raise substantial doubt about our ability to continue as a going concern for at least 12 months from the issuance of the financial statements.”
SEC MD&A · August 6, 2026
Cash runway into Q3 2026.
“We expect that our existing cash, cash equivalents and short-term investments will enable us to fund our operations into the third quarter of 2026”
SEC MD&A · March 5, 2026
Catalyst timeline
- 2026-12-31 · Phase2_Topline · pevifoscorvir — Phase 2 Readout: pevifoscorvir — First topline data from the ongoing Phase 2 trial of pevifoscorvir for chronic HBV.
- 2027-09-30 · Phase2_Topline · pevifoscorvir — Phase 2 Readout: pevifoscorvir — Additional Phase 2 readout for pevifoscorvir.
- 2027-12-31 · Phase2_Topline · pevifoscorvir — Phase 2 Readout: pevifoscorvir — Further Phase 2 readout for pevifoscorvir.
Risks & what to watch (4)›
Key risks
- Going concern uncertainty — Substantial doubt about ability to continue as a going concern for at least 12 months [sec_mda · as of 2026-08-06].
- Limited cash runway — Cash expected to fund operations only into Q3 2026 [sec_mda · as of 2026-03-05].
- No approved products or revenue — Company has no commercial products and no revenue [sec].
- Clinical development risk — Expensive, uncertain process; may never generate data needed for approval [sec_mda · as of 2026-03-05].
What to watch
- Phase 2 topline data for pevifoscorvir, expected by end of 2026 [catalyst].
- Ability to secure additional financing to extend runway beyond Q3 2026 [sec_mda · as of 2026-03-05].
- Progress in MASH and coronavirus programs [sec_mda · as of 2026-03-05].
- Any partnership or collaboration announcements that could provide non-dilutive funding [sec_mda · as of 2026-05-07].
Sources: SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run Aligos Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Aligos Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
4.8 months
D/E 1.08 · 0% dilution
Lead: Phase 2
3 candidates
3 upcoming, next in ~123d
No insider transactions in the last 180 days
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
32
Total value held
$18.2M
| Holder | Shares | Value |
|---|---|---|
| deep track capital, lp | 444,110 | $3.3M |
| alyeska investment group, l.p. | 412,000 | $3.1M |
| vanguard capital management llc | 356,524 | $2.6M |
| marshall wace, llp | 267,135 | $2.0M |
| bank of america corp /de/ | 229,754 | $1.7M |
| summittx capital, l.p. | 148,799 | $1.1M |
| renaissance technologies llc | 100,450 | $746K |
| baker bros. advisors lp | 83,055 | $617K |
| hhlr advisors, ltd. | 76,247 | $567K |
| citadel advisors llc | 54,311 | $404K |
Showing top 10 of 32 institutional holders of Aligos Therapeutics, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 30, 2026- % of float
- 5.2%
- Days to cover
- 5.5
- Shares short
- 275,689
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ALGS short interestGovernance
Frequently asked questions
What is the AI investment thesis for Aligos Therapeutics, Inc.?
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for chronic hepatitis B (HBV) and other liver and viral diseases, with its lead candidate pevifoscorvir sodium in Phase 2 trials.
What is Aligos Therapeutics, Inc.'s lead drug candidate?
Aligos Therapeutics, Inc.'s most advanced tracked candidate is ALG-055009 (Phase 2) for MASH and obesity.
What is Aligos Therapeutics, Inc.'s next catalyst?
Aligos Therapeutics, Inc.'s next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: pevifoscorvir" — expected December 31, 2026.
Who is the CEO of Aligos Therapeutics, Inc.?
Dr. Lawrence M. Blatt MBA, Ph.D. is the chief executive officer of Aligos Therapeutics, Inc. (ALGS).
Where is Aligos Therapeutics, Inc. headquartered?
Aligos Therapeutics, Inc. (ALGS) is headquartered in South San Francisco, CA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.